Nature Communications (Nov 2017)
Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers
- Manaswini Sivaramakrishnan,
- Kathleen D. McCarthy,
- Sébastien Campagne,
- Sylwia Huber,
- Sonja Meier,
- Angélique Augustin,
- Tobias Heckel,
- Hélène Meistermann,
- Melanie N. Hug,
- Pascale Birrer,
- Ahmed Moursy,
- Sarah Khawaja,
- Roland Schmucki,
- Nikos Berntenis,
- Nicolas Giroud,
- Sabrina Golling,
- Manuel Tzouros,
- Balazs Banfai,
- Gonzalo Duran-Pacheco,
- Jens Lamerz,
- Ying Hsiu Liu,
- Thomas Luebbers,
- Hasane Ratni,
- Martin Ebeling,
- Antoine Cléry,
- Sergey Paushkin,
- Adrian R. Krainer,
- Frédéric H.-T. Allain,
- Friedrich Metzger
Affiliations
- Manaswini Sivaramakrishnan
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Kathleen D. McCarthy
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Sébastien Campagne
- Department of Biology, ETH Zurich
- Sylwia Huber
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Sonja Meier
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Angélique Augustin
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Tobias Heckel
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Hélène Meistermann
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Melanie N. Hug
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Pascale Birrer
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Ahmed Moursy
- Department of Biology, ETH Zurich
- Sarah Khawaja
- Department of Biology, ETH Zurich
- Roland Schmucki
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Nikos Berntenis
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Nicolas Giroud
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Sabrina Golling
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Manuel Tzouros
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Balazs Banfai
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Gonzalo Duran-Pacheco
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Jens Lamerz
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Ying Hsiu Liu
- Cold Spring Harbor Laboratory
- Thomas Luebbers
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Hasane Ratni
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Martin Ebeling
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- Antoine Cléry
- Department of Biology, ETH Zurich
- Sergey Paushkin
- SMA Foundation
- Adrian R. Krainer
- Cold Spring Harbor Laboratory
- Frédéric H.-T. Allain
- Department of Biology, ETH Zurich
- Friedrich Metzger
- F. Hoffmann-La Roche Ltd., Pharma Research & Early Development, Roche Innovation Center Basel
- DOI
- https://doi.org/10.1038/s41467-017-01559-4
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 13
Abstract
Small molecules correcting the splicing deficit of the survival of motor neuron 2 (SMN2) gene have been identified as having therapeutic potential. Here, the authors provide evidence that SMN2 mRNA forms a ribonucleoprotein complex that can be specifically targeted by these small molecules.